![]() |
Name |
Xylarolide A
|
Molecular Formula | C22H28O7 | |
IUPAC Name* |
2-(4,5-dihydroxy-10-oxo-2-propyl-2,3,4,5-tetrahydrooxecin-3-yl)propyl4-hydroxybenzoate
|
|
SMILES |
CCCC1OC(=O)C=CC=CC(O)C(O)C1C(C)COC(=O)c1ccc(O)cc1
|
|
InChI |
InChI=1S/C22H28O7/c1-3-6-18-20(21(26)17(24)7-4-5-8-19(25)29-18)14(2)13-28-22(27)15-9-11-16(23)12-10-15/h4-5,7-12,14,17-18,20-21,23-24,26H,3,6,13H2,1-2H3/b7-4+,8-5-/t14-,17+,18-,20?,21-/m1/s1
|
|
InChIKey |
PDHKSNNRJJEEIM-BLMILVTQSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 404.46 | ALogp: | 2.4 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 113.3 | Aromatic Rings: | 2 |
Heavy Atoms: | 29 | QED Weighted: | 0.624 |
Caco-2 Permeability: | -4.805 | MDCK Permeability: | 0.00004620 |
Pgp-inhibitor: | 0.913 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.342 |
30% Bioavailability (F30%): | 0.984 |
Blood-Brain-Barrier Penetration (BBB): | 0.115 | Plasma Protein Binding (PPB): | 97.47% |
Volume Distribution (VD): | 0.342 | Fu: | 1.32% |
CYP1A2-inhibitor: | 0.178 | CYP1A2-substrate: | 0.123 |
CYP2C19-inhibitor: | 0.833 | CYP2C19-substrate: | 0.091 |
CYP2C9-inhibitor: | 0.741 | CYP2C9-substrate: | 0.945 |
CYP2D6-inhibitor: | 0.076 | CYP2D6-substrate: | 0.213 |
CYP3A4-inhibitor: | 0.849 | CYP3A4-substrate: | 0.226 |
Clearance (CL): | 13.859 | Half-life (T1/2): | 0.917 |
hERG Blockers: | 0.12 | Human Hepatotoxicity (H-HT): | 0.091 |
Drug-inuced Liver Injury (DILI): | 0.518 | AMES Toxicity: | 0.017 |
Rat Oral Acute Toxicity: | 0.518 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.676 | Carcinogencity: | 0.233 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.278 |
Respiratory Toxicity: | 0.017 |